.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
McKinsey
Cipla
Accenture
Express Scripts
Argus Health
US Army
Farmers Insurance
Healthtrust
Teva

Generated: September 25, 2017

DrugPatentWatch Database Preview

Lilly Company Profile

« Back to Dashboard

What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?

LILLY has one hundred and thirty approved drugs.

There are twenty-six US patents protecting LILLY drugs and there have been two Paragraph IV challenges on LILLY drugs in the past three years.

There are six hundred and thirty-three patent family members on LILLY drugs in sixty-five countries.

Summary for Applicant: Lilly

Patents:26
Tradenames:119
Ingredients:102
NDAs:130
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
NOVRAD
levopropoxyphene napsylate anhydrous
CAPSULE;ORAL012928-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lilly
FORTEO
teriparatide recombinant human
INJECTABLE;SUBCUTANEOUS021318-002Jun 25, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Lilly
NEBCIN
tobramycin sulfate
INJECTABLE;INJECTION050519-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Lilly
KEFLIN IN PLASTIC CONTAINER
cephalothin sodium
INJECTABLE;INJECTION062549-001Sep 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-005Sep 9, 1997ABRXYesNo► Subscribe► Subscribe ► Subscribe
Lilly
CECLOR
cefaclor
FOR SUSPENSION;ORAL050522-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Lilly
FORTEO
teriparatide recombinant human
INJECTABLE;SUBCUTANEOUS021318-001Nov 26, 2002DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Lilly
DIETHYLSTILBESTROL
diethylstilbestrol
TABLET, DELAYED RELEASE;ORAL004039-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lilly
PAGITANE
cycrimine hydrochloride
TABLET;ORAL008951-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-001Apr 6, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-003Apr 6, 2000► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-002Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-004Apr 6, 2000► Subscribe► Subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-004Dec 24, 2003► Subscribe► Subscribe
Lilly
HUMALOG MIX 50/50 KWIKPEN
insulin lispro protamine recombinant; insulin lispro recombinant
INJECTABLE;INJECTION021018-002Sep 6, 2007► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
INJECTABLE;INTRAMUSCULAR021253-001Mar 29, 2004► Subscribe► Subscribe
Lilly
DECABID
indecainide hydrochloride
TABLET, EXTENDED RELEASE;ORAL019693-002Dec 29, 1989► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-001Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-001Sep 30, 1996► Subscribe► Subscribe
Lilly
ZYPREXA
olanzapine
TABLET;ORAL020592-001Sep 30, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for LILLY drugs

Drugname Dosage Strength Tradename Submissiondate
pemetrexed disodium
For Injection750 mg/vial
ALIMTA
10/6/2016
teriparatide
Injection250 mcg/mL, 2.4 mL prefilled Pen
FORTEO
7/27/2015
pemetrexed disodium
For Injection1000 mg/vial
ALIMTA
6/27/2012
duloxetine hydrochloride
Delayed-release Capsules40 mg
CYMBALTA
5/10/2012
tadalafil
Tablets2.5 mg
CIALIS
10/14/2008
duloxetine hydrochloride
Delayed-release Capsules20 mg, 30 mg and 60 mg
CYMBALTA
8/4/2008
pemetrexed disodium
For Injection100 mg/vial
ALIMTA
7/1/2008
olanzapine and fluoxetine hydrochloride
Capsules3 mg/25 mg
SYMBYAX
5/8/2008
pemetrexed disodium
For Injection500 mg/vial
ALIMTA
2/4/2008
tadalafil
Tablets5 mg, 10 mg and 20 mg
CIALIS
11/21/2007
gemcitabine
For Injection2 g/vial
GEMZAR
8/24/2007
atomoxetine hydrochloride
Capsules10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg
STRATTERA
5/29/2007
gemcitabine
For Injection1g/vial
GEMZAR
11/14/2005
gemcitabine
For Injection200 mg/vial
GEMZAR
11/1/2005
olanzapine and fluoxetine hydrochloride
Capsules6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg
SYMBYAX
1/10/2005

Premature patent expirations for LILLY

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Lilly

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,857,791Medication dispensing apparatus with gear set having drive member accommodating opening► Subscribe
4,996,206 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives► Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use► Subscribe
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction► Subscribe
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use► Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors► Subscribe
6,841,167 .beta.-carboline pharmaceutical compositions► Subscribe
5,248,775 Pyrrolo(2,3-d)pyrimidines► Subscribe
6,025,494 Tetracyclic derivatives, process of preparation and use► Subscribe
7,427,275Medication dispensing apparatus with triple screw threads for mechanical advantage► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Lilly Drugs

Country Document Number Estimated Expiration
Israel146098► Subscribe
Canada2181377► Subscribe
China1513452► Subscribe
Russian Federation2142463► Subscribe
World Intellectual Property Organization (WIPO)0108687► Subscribe
European Patent Office0846118► Subscribe
New Zealand333913► Subscribe
China1112928► Subscribe
Indonesia25704► Subscribe
Slovakia3898► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Lilly Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
213Luxembourg► SubscribePRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
C0020France► SubscribePRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110
2004005Lithuania► SubscribePRODUCT NAME: INSULIN DETEMIR
2004005,C0792290Lithuania► SubscribePRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C/GB05/011United Kingdom► SubscribePRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
/2008Austria► SubscribePRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
C/GB96/058United Kingdom► SubscribePRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
2013000061Germany► SubscribePRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Johnson and Johnson
Colorcon
Fuji
Moodys
Daiichi Sankyo
Farmers Insurance
Express Scripts
Cerilliant
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot